18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

  • Rik Vandenberghe
  • Koen Van Laere
  • Adrian Ivanoiu
  • Eric Salmon
  • Christine Bastin
  • Eric Triau
  • Hasselbalch, Steen
  • Law, Ian
  • Allan Andersen
  • Ejnar Alex Kørner
  • Lennart Minthon
  • Gaëtan Garraux
  • Natalie Nelissen
  • Guy Bormans
  • Chris Buckley
  • Rikard Owenius
  • Lennart Thurfjell
  • Gill Farrar
  • David J Brooks
The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.
OriginalsprogEngelsk
TidsskriftAnnals of Neurology
Vol/bind68
Udgave nummer3
Sider (fra-til)319-29
Antal sider11
ISSN0364-5134
DOI
StatusUdgivet - 2010

ID: 34091263